PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 20, 2026American Journal of Respiratory and Critical Care Medicine0 citations

Safety And Efficacy Of Sotatercept In Patients With Pulmonary Arterial Hypertension

B106-21 Safety and Efficacy of Sotatercept in Pulmonary Arterial Hypertension Patients With Comorbidities

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Comorbidities affect the tolerability and blunt the response to pulmonary hypertension therapies, prompting evaluation of Sotatercept's efficacy and tolerability in patients with PAH and multiple comorbidities.

Does Sotatercept improve hemodynamics and functional capacity in patients with pulmonary arterial hypertension and multiple comorbidities?

Population

23 PAH patients initiated on Sotatercept with pre- and post-treatment hemodynamic data

Comparison

Sotatercept treatment assessed before vs after therapy

Design

Real-world observational study

Follow-up

Median period of 14 months

Key result

Sotatercept treatment in PAH patients with comorbidities significantly improved 6-minute walk distance (327 to 377m, p=0.011) and mean pulmonary arterial pressure (47 to 36 mmHg, p<0.001).

Authors

MMM J MaestreMCM ChavarriaMSM U Syed

Discussion

Loading...

Member takes

Overview

Cautious interpretation needed for sotatercept in comorbid PAH; leaves open benefit in larger randomized trials.

Key Points

  • This study aims to assess the efficacy and tolerability of Sotatercept in patients with pulmonary arterial hypertension (PAH) having multiple comorbidities.
  • 130 patients initiated on Sotatercept with 23 having hemodynamic data available for analysis.
  • Evaluated hemodynamic parameters like mean pulmonary arterial pressure (mPAP), pulmonary vascular resistance (PVR), and functional outcomes at baseline and after ≥6 months of therapy.
  • Analyzed real-world data focusing on improvements in exercise capacity and laboratory metrics.
  • Mean pulmonary arterial pressure improved from 47 mmHg to 36 mmHg (p < 0.001).
  • 6-minute walk distance increased from 327m to 377m (p = 0.011).
  • NT-proBNP levels reduced from 541.00 pg/mL to 194.00 pg/mL (p = 0.006).

Study Design

Type

Observational (n=23)

Structured PICO

Does Sotatercept improve hemodynamics and functional capacity in patients with pulmonary arterial hypertension and multiple comorbidities?

P
Population
23 patients with pulmonary arterial hypertension (PAH) and available right heart catheterization data (from a larger cohort of 130), mean age 52 ± 14 years, 83% female, with high rates of comorbidities including obesity (52%), OSA (52%), and hypertension (43%).
I
Intervention
Sotatercept (median 14 doses over a median period of 14 months) added to stable background therapy (83% on triple therapy).
O
Outcome
Changes in hemodynamic parameters (mPAP, PVR), functional parameters (6-minute walk distance, functional class, REVEAL Lite 2 score), and laboratory parameters (NT-proBNP, hemoglobin) from baseline to at least 6 months after therapy.surrogate

Main Result

p-value: p=<0.001

Cite This Study

Maestre et al. (2026) conducted an observational in Pulmonary arterial hypertension (PAH) with comorbidities (n=23). Sotatercept was evaluated on Hemodynamic and functional parameters including 6-minute walk distance, mean pulmonary arterial pressure, and pulmonary vascular resistance (p=<0.001). Sotatercept treatment in PAH patients with comorbidities significantly improved 6-minute walk distance (327 to 377m, p=0.011) and mean pulmonary arterial pressure (47 to 36 mmHg, p<0.001).

synapsesocial.com/papers/6a0d5114f03e14405aa9d671https://doi.org/10.1093/ajrccm/aamag162.5752
View Full Paper
Ask AI
Bookmark
Share